In an interim analysis of REALITY-01, an RWE study of patients who received T-DXd through an early access program or after marketing authorization following at least two lines of prior therapy for metastatic/unresectable HER2-positive breast cancer, median rwPFS was 17.4 months (32). Here, ERBB2 is linked to breast carcinoma.